Pharma power play hinges mostly on the initial R&D race to market dominance. Research innovation and investment has enticing potential. The Pharmaceutical industry pipeline was noted to have seen a 5% year on year increase in the first quarter of 2016 1 . Just under 70% of that pipeline is covered by the therapy areas of oncology, infectious diseases and central nervous system disorders. The same report noted that the price to bring a single novel drug to market rested at around $2.6 billion in 2015.
n the pharmaceutical and fine chemical industries, reactions are often exothermic. Though they have inherent safety hazards at small scale, these risks can be alleivated by operating in semi-batch mode with solid or reagent dosing. While monitoring batch temperature can be used to control thermal risk, upon scale-up to larger jacketed glass reactors, heat removal becomes limited due to decreasing surface area to volume ratios, and this introduces new risks.
To meet the growing demand, medical manufacturing is adapting disruptive technologies that are reshaping manufacturing as a whole and displacing established practices. Here’s a look at some of the disruptive trends that are transforming medical manufacturing.
Following a quarter that featured reports stating that Novartis had dramatically redistributed its cell and gene therapy unit 1 and saw the public focus turn once again to drug price hikes, Pharma IQ brings you the pharma, biotech and life sciences news highlights for Q3 of 2016.
Currently, two trends are in focus for the clinical trial supply chain: patient centricity and the usage of the Internet of Things (IoT) in clinical trials. Both components are driven by the need to shorten clinical development timelines, reduce costs and improve data quality. The clinical supply chain can contribute significantly to these objectives.
Earlier this month, Industry members gathered to tackle challenges and contribute to the discussion surrounding cell and gene therapies and their manufacture.
A new technology referred to as an artificial nose has the ability to detect a rare progressive lung disease from a patient’s breath.
The first respiratory biomedicine from AstraZeneca received primary and key secondary endpoints in the third phase of clinical trials. The therapy, Benralizumab, when combined with standard medicine was seen to significantly reduce severity of asthma symptoms and enhanced lung function with individuals which harbour an eosinophilic phenotype.
G-PN is a new vaccine which is a whole cell pneumococcal treatment that is inactivated by the presence of gamma irradiation. This biologic is said to have the capability to eliminate all of the 90 known structures of the pneumococcus bacteria - Streptococcus pneumonia.
Remote working is exploding as a result of mobile technologies. A growing segment of the workforce prefers it, and it saves huge spend on real estate and related costs. But lagging behind the rapid technology expansion is well thought through organizational strategy to absolutely ensure that remote workers are as productive and as engaged as their in-house counterparts.